Healthcare Services

Global Cholestatic Pruritus Market Expected to Reach $25.98 Billion by 2030 with 5.1% CAGR

March 31, 2026April 1, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Expected For The Cholestatic Pruritus Market At The End Of The 2026–2030 Forecast Period?

The cholestatic pruritus market size has seen substantial growth in recent years. This market is anticipated to expand from $20.22 billion in 2025 to $21.3 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 5.3%. The drivers behind its past growth include the increasing prevalence of chronic liver diseases, the restricted efficacy of conventional antihistamines, the development of hepatology specialty care, a rise in the diagnosis of cholestatic disorders, and the expansion of supportive care treatments.

The cholestatic pruritus market is poised for substantial expansion over the next few years. It is projected to achieve a value of $25.99 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 5.1%. This anticipated growth can be attributed to several factors, including the increasing approval of innovative therapies, a heightened focus on enhancing patients’ quality of life, the wider availability of targeted drugs for liver diseases, escalating investment in rare disease research, and the growing embrace of personalized treatment plans. Significant trends during this forecast period are expected to encompass the increased development of targeted anti-pruritic treatments, a rising emphasis on symptom-specific therapeutic approaches, the expanded utilization of oral bile acid modulators, a broadening of research into liver disease management, and the implementation of more patient-centered care strategies.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21140&type=smp

Which Market Drivers Are Supporting The Expansion Of The Cholestatic Pruritus Market?

The increasing prevalence of liver diseases is projected to stimulate the expansion of the cholestatic pruritus market in the future. Liver diseases represent a wide array of conditions impacting liver function, encompassing infections, autoimmune disorders, genetic illnesses, and damage from toxins, which can result in inflammation, scarring, or eventual liver failure. The rising incidence of these liver conditions is fueled by increasing rates of obesity, diabetes, alcohol consumption, viral hepatitis infections, and exposure to environmental toxins and other factors. Cholestatic pruritus assists in the identification and management of liver diseases by serving as a critical symptom that signals impaired bile flow, often prompting additional investigation and treatment of the underlying hepatic issues. For instance, in 2023, according to the Office for Health Improvement and Disparities (OHID), a UK-based government agency, England saw 85,665 hospital admissions for liver disease during the financial year ending in 2023. Therefore, the increasing prevalence of liver diseases will drive the growth of the cholestatic pruritus market.

What Segment Types Make Up The Cholestatic Pruritus Market?

The cholestatic pruritus market covered in this report is segmented –

1) By Disease Type: Primary Biliary Cholangitis (PBC), Primary Sclerosing Cholangitis (PSC), Intrahepatic Cholestasis Of Pregnancy (ICP), Other Disease Types

2) By Treatment Type: Medications, Phototherapy, Other Treatment Types

3) By Route Of Administration: Oral, Topical, Injectable

4) By End-User: Hospitals, Clinics, Ambulatory Care Centers, Homecare

Subsegments:

1) By Primary Biliary Cholangitis (PBC): Early-Stage PBC, Advanced PBC, PBC With Cirrhosis, PBC With Liver Failure

2) By Primary Sclerosing Cholangitis (PSC): Classic PSC, PSC With Ulcerative Colitis, PSC With Bile Duct Strictures

3) By Intrahepatic Cholestasis Of Pregnancy (ICP): Mild ICP, Severe ICP, ICP With Preterm Birth Risk

4) By Other Disease Types: Alcoholic Cholestasis, Drug-Induced Cholestasis, Viral Hepatitis-Induced Cholestasis, Genetic Cholestasis Disorders

Which Trends Are Shaping The Future Of The Cholestatic Pruritus Market?

Companies active in the cholestatic pruritus market are prioritizing the creation of innovative solutions, specifically oral solutions, to enhance symptom control, boost patient adherence, and deliver specific relief by targeting the underlying causes of bile salt accumulation and inflammation. An oral solution for treating cholestatic pruritus represents a liquid drug designed to diminish the buildup of bile acids and soothe intense itching in patients experiencing cholestasis. As an illustration, in March 2024, Mirum Pharmaceuticals Inc., a US-based biopharmaceutical company, was granted authorization by the U.S. Food and Drug Administration (FDA) for LIVMARLI (maralixibat) oral solution to address cholestatic pruritus in individuals aged five and older who have progressive familial intrahepatic cholestasis (PFIC). This once-daily, orally administered ileal bile acid transporter inhibitor has been designated as a breakthrough therapy for PFIC type 2. LIVMARLI is anticipated to profoundly benefit patients with cholestatic pruritus linked to PFIC, providing a crucial therapeutic alternative for those with the rarest subtypes.

Who Are The Key Players Driving Competition In The Cholestatic Pruritus Market?

Major companies operating in the cholestatic pruritus market are GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Merck KGaA, Incyte Corporation, Ipsen Pharma, CANbridge Pharmaceuticals Inc., Escient Pharmaceuticals Inc., Mirum Pharmaceuticals Inc., Albireo Pharma Inc., Cara Therapeutics Inc., CymaBay Therapeutics Inc., Gilead Sciences Inc., Zydus Lifesciences, Genfit SA, NGM Biopharmaceuticals Inc., Calliditas Therapeutics AB, Avior Inc, Travere Therapeutics Inc., 89bio, Hepion Pharmaceuticals, Liminal BioSciences, ProQR Therapeutics NV.

Read the full cholestatic pruritus market report here:

https://www.thebusinessresearchcompany.com/report/cholestatic-pruritus-global-market-report

How Is The Cholestatic Pruritus Market Distributed Across Key Geographic Regions?

North America was the largest region in the cholestatic pruritus market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cholestatic pruritus market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Cholestatic Pruritus Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21140&type=smp

Browse Through More Reports Similar to the Global Cholestatic Pruritus Market 2026, By The Business Research Company

Gastrointestinal Stromal Tumor Global Market Report

https://www.thebusinessresearchcompany.com/report/gastrointestinal-stromal-tumor-global-market-report

Liver Cancer Diagnostics Global Market Report

https://www.thebusinessresearchcompany.com/report/liver-cancer-diagnostics-global-market-report

Invasive Ductal Carcinoma Therapeutics Global Market Report

https://www.thebusinessresearchcompany.com/report/invasive-ductal-carcinoma-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795